• China lends Nigeria Dollars 2bn in exchange for oil talks. • Ft com site : China oils Nigeria talks with loan

investigation for corruption.
Extension to food supervision
On Apr. 16, 2003, the first session of Tenth National People's Congress approved the transition of the SDA to the State Food and Drug Administration.
At the same time, the SARS virus was sweeping across many parts of China. The SFDA set up a SARS drug approval team and opened a fast track approval system for anti-SARS medicines. In 2004, the SFDA created a similar fast track system for treatments against bird flu.
Meanwhile, the newly broadened agency still shared food supervisory responsibilities with various other government agencies, such as the quality supervision and inspection, agricultural and industrial & commercial administrations, resulting in inefficient management of the food quality control system.
In April 2004, matters came to a head when 13 babies in eastern Anhui province’s Fuyang City died after being fed milk of inferior quality, drawing widespread condemnation for the year-old SFDA. Since then, adverse events which received high levels of publicity include faulty pacemakers, postoperative breakage of pedicle screws systems and displacement of breast implants, as well as the deaths causing Xinfu and fake armillarisni A injection events in 2006.
Anti-corruption campaign
A campaign to eliminate corruption in the drug supervision field was launched in 2005. In June 2005, Zheng Xiaoyu was removed as head of the SFDA, to be succeeded by Shao Mingli.
In July 2005, Hao Heping, the former chief of the medical device division within the SFDA, was arrested. In November, Zhang Ping, the former president of Guangzhou Tianzhijiao Pharmaceutical Developed Co. Ltd. was arrested and, in his confession, named government officials and experts who had received bribes.
In January 2006, Cao Wenzhuang, the former chief of the SFDA’s drug registration division was investigated. On Dec. 22 2006, Zheng Xiaoyu was investigated, and several days later, Zhang Shusen, the director of Liaoning provincial drug administration, was arrested.
In July last year, Zheng was executed for corruption. Doubts about the ability of the SFDA to properly supervise food and drug safety have been mounting, and calls increased for a "super health ministry" or "health commission", which would include the functions of the SFDA and the MoH.
SFDA under MoH umbrella
As of Mar. 15, the SFDA is now under the management of the Ministry of Health.  
Following the move, the ministry will be responsible for the formulation of food and safety standards and compiling the national pharmacopeia and the national essential drugs list, a list of inexpensive and commonly used drugs which all Chinese patients should have access to. The SFDA will continue to grant approvals to food-related entities and supervise food safety, as well as oversee the development, production, distribution, application and safety of drugs.
"Whether the SFDA is managed by the MoH or not is not really the issue. The most important point is that the responsibilities of the two agencies should be clearly delineated and adhered to," Professor Gu Xin from Beijing University told Interfax.
Shao Mingli said that the government is investigating and planning whether local drug administrations will be placed under the management of local health departments.
Index Code Wednesday 19/03/2008 Wednesday 26/03/2008 Weekly change (%)

Shanghai Composite Index 000001 3032.22 2958.72 -2.42

Shanghai A Share Index 000002 3947.93 3784.29 -4.14

Shanghai B Share Index 000003 254.73 261.4 2.62

Shanghai 180 Index 000010 8645.95 8627.52 -0.21

Shenzhen Composite Index 9989 1120.04 1153.64 3.00

Shenzhen A Share Index 9990 1178.71 1213.19 2.93

Shenzhen B Share Index 9991 518.78 554.86 6.95

Shenzhen Sub 9901 13044.2 13489.09 3.41

Shenzhen Sub A Share Index 9902 13749.85 14218.8 3.41

Shenzhen Sub B Share Index 9903 4060.93 4426.87 9.01

Shanghai Composite Index is the overall statistic quotation reflecting dynamism of the Shanghai Stock Exchange. The index has been published by the Shanghai Stock Exchange since July 15, 1991. The index basic unit is a "point". December 19, 1990 was chosen to be a benchmark, with 100 points set as the starting day value. In 1992 - 1993, the Shanghai Stock Exchange started issuing supplementary indices to diversify quotations of various securities (A-shares, B-shares and classified indices on diverse sectors of the economy) - the Shanghai Composite Index became a comprehensive complex set of share prices.
Shenzhen Composite Index is the overall statistic quotation reflecting the dynamism of the Shenzhen Stock Exchange. The Shenzhen Stock Exchange (SZSE) has been publishing the index since April 4, 1991. The basic unit of the index is a "point". April 3, 1991 was chosen to be a benchmark, with 100 points set as the starting day value. To diversify quotations of various securities (Shenzhen A-shares, B-shares, and classified indices on diverse sectors of the economy), the Shenzhen Stock Exchange began issuing supplementary indices from October 6, 1994, which made the Shenzhen Composite Index a comprehensive complex set of share prices. From January 23, 1995, SZSE started publishing sub indices (Shenzhen Sub A-shares and Sub B-shares), reflecting the dynamism of 40 main companies. July 20, 1994 was chosen to be a benchmark, with 1,000 points as the starting day value.
Security Code Price on Wednesday

19/03/2008 (RMB) Price on Wednesday

26/03/2008 RMB) Weekly change (%) Volume

Double Crane Pharma 600062 27.8 28.19 1.40 7,224,576

Ginwa Enterprise 600080 6.25 6.23 -0.32 11,946,826

Tongrentang 600085 24.65 25.15 2.03 14,486,300

Taiji Industry Group 600129 13.67 14.37 5.12 6,953,216

Tiantan Biological 600161 29.99 26.03 -13.20 14,570,593

Fosun Pharma 600196 15 15.74 4.93 47,135,673

Jinyu Group 600201 12.98 13.68 5.39 11,798,701

Tibet Rhodiola Pharma 600211 11.85 12.89 8.78 13,469,465

Zhejiang Medicine 600216 19.47 22.49 15.51 42,636,698

Joyline & Joysun Pharma 600222 6.8 6.96 2.35 9,878,426

Topfond Pharma 600253 6.67 6.7 0.45 18,962,189

Hisun Pharma 600267 21.2 19.21 -9.39 22,552,864

Hengrui Medicine 600276 47.5 45.76 -3.66 2,619,410

Lingrui Pharma 600285 11.45 12.19 6.46 20,496,481

Merro Pharma 600297 10.07 10.95 8.74 5,214,957

Zhongxin Pharma 600329 11.22 10.35 -7.75 16,535,257

Guangzhou Pharma 600332 12.89 13.42 4.11 7,509,627

Yabao Pharma 600351 14.28 15.99 11.97 17,085,748

Joincare Pharma 600380 20.03 20.99 4.79 19,246,994

ST Jintai 600385 10.34 9.96 -3.68 28,118,613

Modern Pharma 600420 10.69 11.21 4.86 10,060,331

Spring Biological 600421 8.59 8.59 0.00 0

Kunming Pharma 600422 7.46 7.69 3.08 23,182,511

Pientzehuang Pharma 600436 35.68 32.68 -8.41 3,559,402

Dikang Sci& Tech Pharma 600466 12.97 12.97 0.00 0

Qianjin Pharma 600479 33.42 32.4 -3.05 2,379,535

China National Medicines 600511 52.87 58.67 10.97 1,540,862

Lianhuan Pharma 600513 13.27 13.89 4.67 2,114,403

Kangmei Pharma 600518 9.47 9.76 3.06 55,747,763

G Huahai Pharma 600521 22.7 22.61 -0.40 5,456,646

Jiaoda Only 600530 10.08 10.45 3.67 11,659,246

Tasly Pharma 600535 17.34 17.78 2.54 13,474,094

Beihai Guofa Biological 600538 11.36 12.36 8.80 75,586,430

Beisheng Pharma 600556 9.77 10.24 4.81 42,738,565

Kanion Pharma 600557 28.99 31.46 8.52 3,956,921

Qianjiang Pharma 600568 9.69 10.35 6.81 6,584,743

Conba Pharma 600572 19.82 20.33 2.57 5,196,814

Yibai Pharma 600594 13.17 14.55 10.48 18,039,124

Harbin Pharma 600664 11.69 10.91 -6.67 88,758,255

Southwest Pharma 600666 11.55 13.19 14.20 11,212,621

Tianmu Pharma 600671 10.41 10.44 0.29 5,265,958

Nanjing Medicine 600713 12.34 12.83 3.97 16,709,444

Jiangzhong Pharma 600750 12.88 12.5 -2.95 28,020,532

Topsun Sci-Tech 600771 12.47 14.38 15.32 14,921,878

Lukang Pharma 600789 6.87 7.07 2.91 35,984,614

Qianjiang Biochemical 600796 12.07 11.73 -2.82 166,812,697

North China Pharma 600812 7.38 7.97 7.99 94,766,950

ST Zhongxi Pharma 600842 9.02 9.82 8.87 9,035,897

Shanghai Pharma 600849 10.23 10.16 -0.68 16,053,438

Star Lake Bioscience 600866 5.74 5.79 0.87 41,359,137

Tonghua Dongbao Medicine 600867 12.81 14.27 11.40 35,376,616

S& P Pharma 600869 15.92 17.84 12.06 4,380,556

Wuhan Jianmin Pharma 600976 8.97 9.04 0.78 9,859,264

Mayinglong Pharma 600993 47.89 46.82 -2.23 2,903,751

Source: Shanghai Securities Exchange
Security Code Price on Wednesday

19/03/2008

(USD) Price on Wednesday

26/03/2008

(RMB) Weekly change (%) Weekly volume

Sanjiu Technology Development 900907 0.77 0.777 0.91 3,360,275

Source: Shanghai Securities Exchange
Security Code Price on Wednesday

19/03/2008

(RMB) Price on Wednesday

26/03/2008

(RMB) Weekly change (%) Weekly volume

Accord Pharma 000028 19.09 19.8 3.72 3,310,961

Neptunus Bioengineering 000078 8.29 8.3 0.12 60,294,241

Fengyuan Pharma 000153 6.99 6.9 -1.29 9,330,334

Dong'e Ejiao 000423 26.59 26.5 -0.34 7,333,665

Livzon Pharma Group 000513 26 26.66 2.54 7,452,383

Sihuan Bioengineering 000518 5.49 5.41 -1.46 60,761,392

Baiyunshan A 000522 11.28 11.59 2.75 11,074,268

Yunnan Baiyao 000538 31.7 29 -8.52 7,110,923

Jilin Pharma 000545 8.95 9.95 11.17 8,118,339

ST Guangxia Industry 000557 6.46 6.68 3.41 33,155,771

Hainan Haiyao 000566 11.45 12.69 10.83 61,151,262

Qinghua Unisplendour Guhan 000590 8.33 8.89 6.72 7,879,153

Tong Jun Ge 000591 12.03 13.54 12.55 10,731,114

North China Pharma 000597 15.99 15.61 -2.38 12,856,203

Sihuan Pharma 000605 15.19 12.8 -15.73 9,057,080

G Aodong Medince 000623 40.39 39.13 -3.12 56,729,685

Changchun Hightech 000661 12.34 13.61 10.29 8,809,402

Apeloa Kangyu 000739 8.7 8.66 -0.46 13,920,109

Guilin Jiqi 000750 3.44 3.44 0.00 0

Xinhua Pharma 000756 7.5 7.7 2.67 12,044,733

ST Tonghua Golden Horse 000766 6.35 6.38 0.47 18,906,309

Southwest Synthetic 000788 12.43 11.52 -7.32 25,061,185

Chengdu Hoist 000790 21.04 23.35 10.98 5,879,551

Jinling Pharma 000919 12.07 12.45 3.15 23,811,846

Guangji Pharma 000952 15.97 16.51 3.38 34,236,188

Huadong Medicine 000963 14.2 16.26 14.51 7,818,782

Jiuzhitang 000989 14.08 14.29 1.49 17,847,899

Chengzhi 000990 12.88 12.91 0.23 8,391,120

Sanjiu Medical & Pharmaceutical 000999 16.27 18.44 13.34 17,374,390

Huapont Medicine 002004 27.05 29.45 8.87 6,710,410

Hualan Bioengineering 002007 44.7 42.44 -5.06 1,223,642

Jingxin Pharma 002020 11.5 11.32 -1.57 8,856,059

Kehua Bioengineering 002022 33.9 34.7 2.36 2,232,314

DaAn Gene 002030 15.15 16.9 11.55 5,002,086

SL Pharma 002038 51.2 53.21 3.93 2,669,642

Source: Shenzhen Securities Exchange
Security Code Price on Wednesday

19/03/2008

(RMB) Price on Wednesday

26/03/2008

(RMB) Weekly change (%) Weekly volume

Accord Pharma B 200028 8 8.22 2.75 584,605

ST Benelux Enterprise 200041 1.16 1.16 0.00 0

Livzon B 200713 12.7 13.22 4.09 1,588,588

Source: Shenzhen Securities Exchange
The 2008 China Pharmaceutical Retail Industry Annual Conference will be held by the China Association of Pharmaceutical Commerce in Wuhan, the capital city of northern China's Hubei province.
This annual conference aims to shed some light on the current market and policy environment for pharmaceutical retail businesses and will also touch on topics such as current trends in mergers and acquisitions in the pharmaceutical industry.
Please note: The date of the conference has been pushed back from March 26 – March 27 and it will now be taking place in late April. For any queries, please contact the conference organizers below.
Date: April 25 - April 26
Location: Wuhan Oriental Hotel, Wuhan, Hubei Province
Hosting Organization: China Association of Pharmaceutical Commerce
Website:
Contact: Ms. Wang Yan
Tel: [phone]
Fax: [phone]
Mr. Mi Tiehua
Tel: [phone]
The 2008 Pharmaceutical Industry Development Forum will invite policy makers from various state administrations, including the research department of the State Council, the National Development and Reform Commission and the State Food and Drug Administration to discuss the current macro-economic environment for the pharmaceutical industry and analyze current developments and reform trends within the industry.
Date: March 29 - March 30
Location: Beijing New Mandarin Hotel
Hosting Organization: China Academy of Social Sciences & China Pharmaceutical Technology Transfer Center
Website:
Contact: Mr. Bi Wenliang
Tel: [phone]
Fax: [phone]
E-mail:
Impact China IV is the leading conference on research & development in China. As the market matures, it is no longer a question of whether you should be considering China as part of your global drug development but when and how to include China in your forward goals. Impact China answers this question with practical guidance for getting business done in China. 
Impact China IV features in-depth presentations from top-tier multinational companies, representing the largest R & D budgets in the world. For a full program and a list of confirmed speakers, please visit the website below, or for more information, please contact ALM Events’ senior event director, Judy Kelly (contact details below).
Date: May 4 – May 6, 2008
Website:
Contact: Judy Kelly, Senior Event Director, ALM/ SRI
Tel: [phone] ext 241,
E-mail:
The 10th (2008) China Venture Capital & Private Equity Forum (CVCF2008) will be held around the theme of “Fostering Favourable Environments for Development & Building up Complete PE/VC Industrial Chain”. CVCF2008 will hear in-depth discussions of the latest issues in the Chinese venture capital industry.
The forum will host over 1400 guests, including:
100+ policy-makers from central and local governments;
400+ global investors (LPs, PE/VC investors, Institutional investors, and investment bankers);   
600+ outstanding fund-seeking entrepreneurs;
The forum will also feature The China Outstanding Enterprise Road Shows & Investment Match Making and Innovative Training Programs for Chinese VCs & Start-up Entrepreneurs. CVCF2008 is the largest forum of its kind in scale, the highest in level, and the number of investment institutions attending, with $40 billion global venture capital gathering in Shenzhen to seek opportunities to invest.
Date: April 11 – April 12
Location: Wuzhou National Guest Hotel, Shenzhen, Guangdong Province
Website:
Contact:
Tel: [phone]
E-mail:
Healthoo.com, set up by the Orient Health Electronic Commercial Company in June 1996, is an internet information service platform covering APIs, pharmaceutical products and terminal distribution. The company, together with Agno Pharma, a U.S.-based international contract research and manufacturing company, are co-sponsoring the pharmaceutical outsourcing conference which provides a forum for both foreign and domestic drug manufacturers to meet and work out cooperative opportunities.
Date: April 17 – April 18, 2008
Location: Ramada Plaza, Nanjing
Website:
Contact: Ms Huifang Wu President, Beijing Orientbit Technology Ltd.
Tel: [phone]-2101
E-mail:
Keep up-to-date with breaking developments within your target industries in China with Interfax-China’s authoritative industry weeklies.
China Investment Weekly (Launch: Q4 2007)
China Real Estate Weekly (Launch: H1 2008)
China Pharmaceuticals & Health Technologies Weekly
China Commodities Daily – Energy & Metals
China Commodities Daily – Grains & Softs
China Energy Weekly
China IT Weekly
China Telecom Weekly
China Metals Weekly
Free trials available.
Strengthen your China strategy through in-depth analysis and intelligence through yearly Special Reports, tailored Custom Research, and periodic Industry Monitoring.
China’s Interventional Medical Device Markets 2007
Clean & Renewable Energy in China 2007 Upcoming Release
China Electricity Industry 2007
China Print Media Industries 2007
China Oil and Gas Industries 2007
China Coal Mine and Safety Equipment Market 2007
China Metals Mining Equipment Market 2007
Special Investigation of Pharmaceutical Sales in Chinese Hospitals 2007
China’s Demand for Power up to 2030
Digital TV Initiatives In China (Exclusive Monthly Update not available for resale)
China Media Investment Report 2006
China Handset Report Quarterly 2004
Coal Mine and Safety Equipment Market in China 2007
China Media Investment Report 2004
China 3G Report 2004
Interfax Mobile Phone Market Report for 2003
Samples available upon request. Purchase full report or subsections.
Strengthen your China strategy through in-depth analysis and intelligence through yearly Special Reports, tailored Custom Research, and periodic Industry Monitoring
Russia & CIS Oil & Gas Weekly
Russia Metals & Mining Weekly
Russia Precious Metals & Gems Weekly
Russia & CIS Banking & Finance Weekly
Russia & CIS Business & Investment Weekly
Russia Insurance Weekly
Russia & CIS IT & Telecom Weekly
Food & Agriculture Weekly
Russia Defense Industry Weekly
Russia & CIS Business Law Weekly
Russia & CIS Statistics Weekly
Central Asia & Caucasus Business Weekly
Eurasia Economic Weekly
Ukraine Business Weekly
Belarus Business Weekly
Russia & CIS Business and Financial Daily
Russia & CIS Energy Daily
Ukraine Business Daily
Russia & CIS Business and Financial Newswire
Russia & CIS Military Information Weekly
Russia & CIS Diplomatic Panorama
Russia & CIS Presidential Bulletin
Russia & CIS Military Daily
Belarus News Daily
Russia & CIS General Newswire
Russia & CIS Announcements
Russia & CIS Military Newswire
Kazakhstan General Newswire
Belarus General Newswire
Belarus Announcements
Ukraine General Newswire
Central Asia General Newswire
Czech Republic & Slovakia Business Weekly
Hungary Business Weekly
Poland Business Weekly
Central Europe Banking & Finance Weekly
Central Europe Energy Weekly
Central Europe IT & Telecom Weekly
Czech Republic Business Daily
Hungary Business Daily
Poland Business Daily
Czech Republic Business Newswire
Hungary Business Newswire
Poland Business Newswire
CH002063.GIFCHINA RESEARCH SERVICES: China insight for China strategy
China Research DivisionPart of a global information group, Interfax-China is the leading source for business intelligence on the P.R.C.

As one of the very few fully independent major international news agencies in mainland China, Interfax-China’s Centre for Economic Analysis is the premier source for unbiased and accurate information and analysis.

Heritage – Our heritage in China provides access to inside market information through our unparalleled network of industry and government sources. As a testament, we are the only non-Chinese news agency to be offered exclusive interviews with China’s top leaders, including President Hu Jintao.

Specialization – Each analyst provides unmatched authoritative insight into their respective sectors due to their highly specialized industry focus and expertise.

Accuracy – Information is drawn from our unrivaled network of inside sources, and cross verified through in-depth interviews with industries experts from government and commercial organizations.

Worldwide Clientele – As a result of our team’s dedication and expertise, Interfax-China enjoys a solid reputation amongst senior industry executives and government officials around the world.

Custom Research
Sound China strategy is built upon sound insight.
Fully understanding China’s shifting terrain is an absolute prerequisite for success. Our team of business specialists focuses directly on your needs to conduct in-depth